PetMeds CEO Transition: Jeff Willard To Succeed Leslie Campbell
PetMed Express (PETS) named Jeff Willard as CEO and President, effective September 28, 2026. Willard succeeds Leslie Campbell, who will retire as Board Chair. Willard has 25 years of leadership experience in consumer and e-commerce. The company aims to return to profitability and growth. PETS stock traded between $1.57 and $4.10 in the past year, closing at $4.10 on Wednesday.
How this was made
The 30-second read
Why it matters
The appointment of Jeff Willard, with extensive e‑commerce experience, aims to drive operational execution and return to sustainable profitability.
Market read
Leadership change is the primary catalyst; investors may reassess valuation based on Willard's track record.
What to watch
Potential integration issues with subsidiary PetCareRx and competitive pressure from larger pet‑care chains.
Background
PetMeds (PETS) is a direct‑to‑consumer pet‑healthcare company operating an online pharmacy. The stock has been volatile, trading $1.57‑$4.10 over the past year.
Ticker impact
PetMeds announced Jeff Willard as new CEO and President effective Sep 28, 2026, replacing interim CEO Leslie Campbell.
Potential short-term upside as investors assess new CEO's track record; medium-term impact depends on execution.
Exec transition is a primary disclosure but limited to leadership; no immediate financial metrics disclosed.
Market effects
May signal renewed focus on profitability for the pet healthcare e‑commerce sector.
Limited to US-listed pet‑care retail segment.
Minimal global impact beyond niche pet‑care investors.
Counterpoint
New CEO could struggle to reverse growth challenges, leading to further downside.
Key entities
- ExecutiveJeff Willard
New CEO and President of PetMeds.
- ExecutiveLeslie C.G. Campbell
Outgoing interim CEO and Board Chair.




